Want to see HK:9887 full AI Analyst Report?
9887 Stock Chart & Stats
HK$92.00
--
Market closed
HK$92.00
--
Day’s Range― - ―
52-Week RangeHK$43.62 - HK$97.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.74M
Market Cap
HK$9.06B
Enterprise ValueHK$8.68B
Total Cash (Recent Filing)HK$1.24B
Total Debt (Recent Filing)HK$373.39M
Price to Earnings (P/E)―
Beta0.91
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding197,670,290
10 Day Avg. Volume814,330
30 Day Avg. Volume1,736,895
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)6.30
Price to Sales (P/S)40.45
P/FCF Ratio-48.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$98.75Price Target Upside7.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Equity BaseThe shift from negative equity in 2022–2023 to approximately 1.27B of positive equity in 2025 materially strengthens the capital structure. This provides a better foundation for operations and investment, although the historical stress shows that financial stability has not yet been fully proven.
Moderate LeverageA debt-to-equity ratio of about 0.22 indicates more moderate leverage than the prior year, reducing balance-sheet pressure and improving financial flexibility. Lower relative debt can help preserve capital for research and commercialization while limiting the burden of financing costs.
Emerging Revenue BaseThe emergence of approximately 197M in 2025 revenue demonstrates that the company has begun generating a meaningful commercial or service-related top line after minimal or zero revenue in earlier periods. If sustained, this could support operating leverage and validate market adoption.
Bears Say
Deep UnprofitabilityA net loss of roughly 235M and a margin near -119% show that current revenue is insufficient to cover the company’s cost base. Persistent deep losses weaken internal funding capacity and make a durable path to breakeven dependent on substantial operating improvement.
Persistent Cash BurnNegative operating and free cash flow across every reported year indicates that the business has not yet converted its activities into self-funded operations. Continued cash burn can constrain research, development, and commercialization unless cash generation improves or external funding remains available.
Unpredictable Revenue HistoryThe sharp revenue swings and presence of zero-revenue years make the company’s commercial trajectory difficult to predict. Inconsistent top-line performance can hinder planning, delay operating leverage, and increase execution risk even after the stronger 2025 revenue result.
Nanjing Leads Biolabs Co., Ltd. Class H News
9887 FAQ
What was Nanjing Leads Biolabs Co., Ltd. Class H’s price range in the past 12 months?
Nanjing Leads Biolabs Co., Ltd. Class H lowest stock price was HK$43.62 and its highest was HK$97.50 in the past 12 months.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s market cap?
Nanjing Leads Biolabs Co., Ltd. Class H’s market cap is HK$9.06B.
When is Nanjing Leads Biolabs Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nanjing Leads Biolabs Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Nanjing Leads Biolabs Co., Ltd. Class H overvalued?
According to Wall Street analysts Nanjing Leads Biolabs Co., Ltd. Class H’s price is currently Undervalued.
Does Nanjing Leads Biolabs Co., Ltd. Class H pay dividends?
Nanjing Leads Biolabs Co., Ltd. Class H does not currently pay dividends.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate?
Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanjing Leads Biolabs Co., Ltd. Class H have?
Nanjing Leads Biolabs Co., Ltd. Class H has 197,670,290 shares outstanding.
What happened to Nanjing Leads Biolabs Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanjing Leads Biolabs Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanjing Leads Biolabs Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$98.75 (7.33% Upside)
HK$98.75 (7.33% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.50%
12-Months-Change
Fundamentals
Return on Equity
-23.34%
Trailing 12-Months
Asset Growth
157.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
9887 Stock 12 Month Forecast
Average Price Target
HK$98.75
▲(7.33% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Viva Biotech Holdings
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―